New hope for rare nerve disease: can a biologic drug cut steroid use?

NCT ID NCT07159893

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a drug called inebilizumab combined with a fast steroid taper in 25 people newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. The goal is to see if this approach can reduce the need for long-term steroids while controlling the disease and improving disability scores. Participants will be followed for relapses and changes in blood markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inebilizumab (a biologic drug) and prednisone (a steroid)
What this could lead to: If it works, this could help newly diagnosed NMOSD patients use less steroids while still controlling the disease, potentially reducing side effects from long-term steroid use.
What could go wrong: This is a very small, early-phase study with only 25 people, so results may not apply broadly. The drug may not reduce relapses or disability as hoped, and there are risks from both the biologic and steroid taper.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease CNS demyelinating autoimmune disease neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES DEMYELINATING AUTOIMMUNE DISEASES, CNS NEUROMYELITIS OPTICA

More trials for these conditions

Other studies related to the condition(s) this trial covers.